Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-2129 tablet approved to conduct clinical trials for treating acute pain.
[Translation]
Hengrui Medicine (600276.SH) announced that recently, its subsidiary Shanghai Hengrui Medicine Co., Ltd. and Shandong Shengdi...
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiaries Shanghai Jiangsu Hengrui Pharmaceuticals Co., Ltd. and Shandong Shengdi Pharmaceutical Co., Ltd. have recently received the approval notice for drug clinical trial of HRS-2129 tablets from the National Medical Products Administration ("NMPA"). The approval allows the product to conduct clinical trials for the treatment of acute pain. According to the information available, there are currently no similar products approved for marketing both domestically and internationally.
Related Articles
CITIC SEC: Taiwan Semiconductor Manufacturing Co., Ltd. Sponsored ADR (TSM.US) Capex guidance exceeds expectations, opening up a major growth cycle for domestic equipment in the advanced process control industry.
Ping An Insurance (02318) joins hands with Yidu City to create Yidu Qingjiang Bay residential base, helping to enhance the high-quality elderly care service experience.
New Stock Preview | Yu Research Hall submitted to the Hong Kong Stock Exchange to construct a modern traditional Chinese medicine service system with a "full life cycle diagnosis and treatment model"
CITIC SEC: Taiwan Semiconductor Manufacturing Co., Ltd. Sponsored ADR (TSM.US) Capex guidance exceeds expectations, opening up a major growth cycle for domestic equipment in the advanced process control industry.
Ping An Insurance (02318) joins hands with Yidu City to create Yidu Qingjiang Bay residential base, helping to enhance the high-quality elderly care service experience.
New Stock Preview | Yu Research Hall submitted to the Hong Kong Stock Exchange to construct a modern traditional Chinese medicine service system with a "full life cycle diagnosis and treatment model"
